Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16172133 | 0.88 | PRMT5 (0.48) | CA1CA2CA9AAK1PRMT5 | |
| SCHEMBL21877189 | 0.87 | CA1 (0.53) | CA1CA2CA9AAK1PRMT5 | |
| SCHEMBL3321408 | 0.86 | PRMT5 (0.49) | CA1CA2CA9AAK1PRMT5 | |
| SCHEMBL1141383 | 0.84 | CA2 (0.55) | CA1CA2CA9AAK1PRMT5 | |
| SCHEMBL6227428 | 0.84 | AAK1 (0.52) | CA1CA2CA9AAK1PRMT5 | |
| SCHEMBL15739681 | 0.83 | CA1 (0.49) | CA1CA2CA9AAK1PRMT5 | |
| SCHEMBL5824153 | 0.83 | AAK1 (0.47) | CA1CA2CA9AAK1PRMT5 | |
| SCHEMBL16947897 | 0.82 | LPL (0.51) | CA1CA2CA9AAK1PRMT5 | |
| SCHEMBL15919266 | 0.82 | AAK1 (0.61) | CA1CA2CA9AAK1PRMT5 | |
| SCHEMBL2554301 | 0.81 | AAK1 (0.52) | CA1CA2CA9AAK1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| EP-2925757-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-9556169-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556169-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556169-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-11-17 | — | — | US | disclosed |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-11-17 | — | — | US | disclosed |
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| WO-2011070299-A1 | TRI-SUBSTITUTED 9H-BETA-CARBOLINE (OR 9H-PYRIDO[3,4-B]INDOLE) DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070299-A1 | TRI-SUBSTITUTED 9H-BETA-CARBOLINE (OR 9H-PYRIDO[3,4-B]INDOLE) DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | CA1 755/4885CA2 135/4885CA9 1226/4885 |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | CA1 755/4885CA2 135/4885CA9 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.